Meaux J B
J Perinat Neonatal Nurs. 1996 Mar;9(4):63-9. doi: 10.1097/00005237-199603000-00008.
Neonatal sepsis continues to be a major source of morbidity and mortality among preterm infants. Although traditional antibiotic therapy continues to be the mainstay of treatment for sepsis, intravenous gammaglobulin (IVIG) is being used in both prevention and treatment of neonatal sepsis as a means to boost the infant's immunocompetence. The article explores the conflicting results of clinical trials testing the efficacy of IVIG for neonatal sepsis. IVIG is discussed with regard to its mechanism of action, pharmacokinetics, dosage and administration, adverse reactions, and nursing implications.
新生儿败血症仍然是早产儿发病和死亡的主要原因。尽管传统抗生素疗法仍然是败血症治疗的主要手段，但静脉注射免疫球蛋白（IVIG）正被用于新生儿败血症的预防和治疗，作为增强婴儿免疫能力的一种方法。本文探讨了测试IVIG治疗新生儿败血症疗效的临床试验中相互矛盾的结果。文中讨论了IVIG的作用机制、药代动力学、剂量和给药方式、不良反应以及护理注意事项。
